PubMed HealthSearch

PubMed · 2654615

[Growth disorders. Recommendations for a practice-oriented classification].

Abstract

Besides acute illnesses, including allergies, growth disturbances are among the most frequent reasons for parents to consult a physician about their children. The basis of diagnosis is a detailed family and personal history. Actual measurement of the parents is necessary for calculation of the patient's target height. The growth data obtained must be charted on percentile curves. Only in the second line of the diagnostic approach should the physician resort to hormone determinations and X-rays of the left hand and wrist for bone age determination. For practical purposes, growth aberrations may be subdivided into normal variants and pathologic processes. The latter may cause proportionate or disproportionate disturbances. For therapeutic reasons it is also important to know whether the deviation of growth started pre- or postnatally. Many growth disorders that develop postnatally are amenable to therapy. They include the following endocrinopathies associated with short stature: isolated growth hormone deficiency (treatment with hGH), congenital adrenal hyperplasia due to enzyme deficiencies (treatment by replacement of cortisol), idiopathic, iso-sexual precocious puberty (treatment with LHRH agonists), and hypothyroidism (treatment with thyroxine). Patients with Turner syndrome benefit from sex hormones only insofar as secondary sexual characteristics develop: these agents do not promote overall growth. The treatment of patients with tall stature by administration of estrogens/gestagens in high dosages is viewed with increasing scepticism. On the average, only a 4-cm reduction in length can be achieved if patients are treated from the onset of puberty through a bone age of 16 years. All secondary growth disturbances are improved by efficient treatment of the primary, underlying disease entity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W M Teller. 1989. [Growth disorders. Recommendations for a practice-oriented classification].. https://pubmed.ncbi.nlm.nih.gov/2654615/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Poor growth in school entrants as an index of organic disease: the Wessex growth study.

OBJECTIVE: To establish whether poor height or height velocity, assessed during the year of school entry, might identify children with previously undiagnosed organic disease. DESIGN: Observation of a total population and their case controls. SETTING: Community base. SUBJECTS: All 14,346 children in two health districts entering school during two consecutive years were screened for height by school nurses, and those whose height lay below the 3rd centile according to Tanner and Whitehouse standards (n = 180) were identified. After excluding 32 with known organic disease, five from ethnic minorities, and three who refused to take part, the remaining 140 short normal children were matched with 140 age and sex matched controls of average height (10th-90th centile) and their height velocities over 12 months measured. MAIN OUTCOME MEASURES: Height, height velocity, previously diagnosed organic disease, and organic disease diagnosed as a result of blood tests and specialist examination. RESULTS: Twenty five of the 180 short children (14%) were already known to have chronic organic disease which could explain their poor growth. Blood tests and specialist examination revealed a further seven with organic disease, which was acquired rather than congenital in three, and a second cause of short stature in one with known organic disease. These eight conditions had been missed at the school entry medical examination. The shorter the child, the more likely an underlying organic disorder, with seven of the 12 children whose heights were more than 3 standard deviations below the mean having some organic disease. Height velocity measured over 12 months, however, did not distinguish short normal children from those with disease or from their matched controls. CONCLUSIONS: Height, but not height velocity, is a useful index for identifying unrecognised organic disease at school entry. The shorter the stature the greater the prevalence of organic disease. The frequency of newly diagnosed remediable disease in this study (1 in 3-4000) is similar to that of neonatal hypothyroidism, which is routinely screened for. Routine investigation of all very short school entrants is recommended.

Body Height

Zinc supplements in breastfed infants.

Among breastfed infants, growth faltering in comparison with reference growth curves is common in both developing and developed countries. We performed a zinc supplementation trial in Paris, France, to find out whether such growth faltering is due to nutritional zinc deficiency. 57 breastfed infants aged 4-9 (mean 5.7) months were randomly assigned to receive either 5 mg zinc daily or a placebo for 3 months. Most of the infants were from low-income immigrant families and the majority were of African origin. Before supplementation there were no significant differences between the zinc and placebo groups in weight, length, or corresponding Z-scores for age. After 3 months' supplementation, the length-for-age Z-score had increased in the zinc group and fallen in the placebo group (+0.21 vs -0.13, p = 0.029). This difference was due mainly to greater linear growth of boys in the zinc than in the placebo group (6.0 vs 4.6 cm, p = 0.02). Weight gain was also significantly greater with zinc supplementation (1.64 vs 1.28 kg, p = 0.047). Among infants breastfed for longer than 4 months, decreases in growth velocity result partly from inadequate zinc intake.

Body Height